Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback